TLSI - NASDAQ
TriSalus Life Sciences, Inc.
$3.29
+3.0%TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
At a Glance
Live SnapshotTriSalus Life Sciences, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
TriSalus Life Sciences, Inc. Income Statement
TLSI • NASDAQ
| TriSalus Life Sciences, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
REVENUE | ||||||
45.2M | 29.4M | 18.5M | 12.4M | 8.4M | 0.0 | |
GROSS PROFIT | ||||||
(7M) | (4.1M) | (2.6M) | (2.3M) | (1.2M) | (0.0) | |
38.2M | 25.3M | 15.9M | 10.1M | 7.2M | 0.0 | |
OPERATING INCOME | ||||||
(65.1M) | (61.5M) | (70.4M) | (46.6M) | (31.2M) | (108.5K) | |
(50.2M) | (43.8M) | (40.5M) | (25.2M) | (17M) | (108.5K) | |
(15M) | (17.7M) | (29.8M) | (21.4M) | (14.2M) | (0.0) | |
-26.9M | -36.2M | -54.5M | -36.4M | -24M | -108.5K | |
PRE-TAX INCOME | ||||||
(5.5M) | (3.1M) | (16K) | (1K) | (1.8M) | (0.0) | |
-5M | -2.7M | 415K | 179K | -1.8M | 3.3K | |
-12.3M | 6.1M | -4.9M | -10.7M | -4.8M | -602.9K | |
-39.2M | -30M | -59.4M | -47.2M | -28.8M | -711.4K | |
NET INCOME | ||||||
(7K) | (6K) | (9K) | (9K) | (3K) | (0.0) | |
-39.2M | -33.2M | -59.4M | -47.2M | -28.8M | -31.8M |
SEC Filings
TLSI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 07, 2026 | April 01, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | March 31, 2026 | December 31, 2025 | 2025 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 20, 2026 | February 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 09, 2026 | February 03, 2026 | 2026 |
Related Guides
Continue your TLSI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.